Immune checkpoint inhibitors and MDSCs

The development of immune checkpoint inhibitors (ICIs) targeting lymphoid cells has remarkedly transformed therapeutic approaches for the treatment of cancer. However, response rates to T cell checkpoint inhibitors vary between individuals with some patients showing minimal to no clinical benefit. In these patients, resistance to this immunotherapy may be partly attributed to myeloid- derived suppressor cells (MDSCs), a heterogeneous population of myeloid progenitors and immature myeloid cells that function as immune suppressors.